The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s glioblastoma multiforme (GBM) treatment market report forecasts the glioblastoma multiforme (GBM) treatment market size to grow to $3.26 Billion by 2027, with a CAGR (compound annual growth rate) of more than 9%.

Learn More On The Glioblastoma Multiforme (GBM) Treatment Market Report 2023 – https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-gbm-treatment-global-market-report

Glioblastoma Multiforme (GBM) Treatment Market Size Forecast
The global glioblastoma multiforme (GBM) treatment market is expected to grow from $2.04 billion in 2022 to $2.26 billion in 2023 at a compound annual growth rate (CAGR) of 10.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The glioblastoma multiforme (GBM) treatment market is expected to grow to $3.26 billion in 2027 at a CAGR of 9.7%.

North America held the largest glioblastoma multiforme (GBM) treatment market share, and Asia-Pacific was the fastest-growing region in 2022.

Key Glioblastoma Multiforme (GBM) Treatment Market Driver ­– Increase In The Prevalence Of Brain Disorders
For instance, according to the report published by Globocan, a US-based international agency for providing global cancer statistics, approximately 308,102 cancer cases were detected for the brain and central nervous system, and 251,329 deaths in the year 2020 globally. Additionally, according to a report published by the American Cancer Society, a US-based voluntary health organization dedicated to eliminating cancer, in 2022, it is estimated around 25,050 malignant tumors of the brain or spinal cord cancer cases will be diagnosed in the US. Therefore, the increasing prevalence of brain disorders is driving the growth of the glioblastoma multiforme (GBM) treatment market.

Request for A Sample Of The Global Glioblastoma Multiforme (GBM) Treatment Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8803&type=smp

Key Glioblastoma Multiforme (GBM) Treatment Market Trend – Advancing In Therapies
Major companies operating in the market are focused on research and development for therapy innovations to sustain their position in the market. For instance, in November 2021, Daiichi Sankyo Company Limited, a Japan-based pharmaceutical company, launched DELYTACT, the first-ever oncolytic virus-based immunotherapy (Teserpaturev) in collaboration with the Institute of Medical Science, The University of Tokyo to treat malignant glioma. Oncolytic viruses refer to genetically modified viruses that are capable of infecting and specifically replicating in cancer cells, eventually causing cell death without damaging healthy cells to inhibit cell proliferation. The unique features of DELYTACT (Teserpaturev) provide patients with the ability to produce immune-boosting molecules or initiate anti-cancer immunity by triggering the multiple mechanisms of the patient’s immune system and also able to kill the tumor cells that have spread to other parts of the brain.

Glioblastoma Multiforme (GBM) Treatment Market Segment
1) By Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy, Immunotherapy
2) By Drug Class: Temozolomide, Bevacizumab, Lomustine, Carmustine Wafers, Other Drug Classes
3) By Route of Administration: Oral, Parenteral, Other Route Of Administrations
4) By End-Use: Hospitals, Clinics, Ambulatory Surgical Centers

Glioblastoma Multiforme (GBM) Treatment Market Major Players and Strategies
Major players in the glioblastoma multiforme (GBM) treatment market are Merck & Co Inc., F. Hoffmann-La Roche AG, Amgen Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Arbor Pharmaceuticals LLC, Amneal Pharmaceuticals Inc., Karyopharm Therapeutics, Sumitomo Pharma Oncology, Novartis AG, Carl Zeiss AG, Varian Medical Systems, Elekta, The Eckert & Ziegler Group, Accord Healthcare Limited, Angiochem Inc., ANI Pharmaceuticals, AstraZeneca plc., Cantex Pharmaceuticals Inc., Celon Laboratories Pvt. Ltd., Diffusion Pharmaceuticals Inc., EnGeneIC, ERC SA, Genenta Science, Jazz Pharmaceuticals Inc., Loxo Oncology Inc., Vascular Biogenics, Zydus Pharmaceuticals Inc., AbbVie, and Genentech Inc.

In April 2022, Elekta, a Sweden-based company that provides radiation therapy, radiosurgery, related equipment, and clinical management for the treatment of cancer signed a global commercial collaboration agreement with GE Healthcare, a US-based manufacturer and distributor of diagnostic imaging agents and radiopharmaceuticals for imaging modalities used in medical imaging procedures. This agreement will be enabling them to provide hospitals with a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy. This partnership will allow the companies to jointly promote solutions for each cancer center’s needs.

The Glioblastoma Multiforme (GBM) Treatment Global Market Report 2023 covers regional data on glioblastoma multiforme (GBM) treatment market size, glioblastoma multiforme (GBM) treatment market trends and drivers, opportunities, strategies, and glioblastoma multiforme (GBM) treatment market competitor analysis. The countries covered in the glioblastoma multiforme (GBM) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Glioblastoma multiforme (GBM) treatment refers to the management and care of a patient suffering from glioblastoma multiforme, a kind of brain or spinal cord tumor that grows quickly. Adults with this primary malignant brain tumor have the highest prevalence rate.

View More Reports Related To The Glioblastoma Multiforme (GBM) Treatment Market –
Neurology Devices Global Market Report 2023
Neurodegenerative Disorder Therapeutics Global Market Report 2023
Neurophysiology Devices And Equipment Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: